Study produces map of pharma industry and API production in Brazil
Brazil is failing to produce the number of active pharmaceutical ingredients in order to produce the drugs it needs, writes Juliane Carvalho of Brazil Pharma News.
Brazil is the leading pharmaceutical market in Latin America and the sixth in the world, worth around $28.5 billion in 2012, according to IMS Health data. However, the country produces only about 1% of active pharmaceutical ingredients (API) compared to total imports of these substances. The result is a deficit of $2.4 billion in this segment according to 2010 data. Researchers at the Brazil-based Oswald Cruz Foundation ( Fiocruz) drew a detailed mapping of the companies, their technical and operational capacity and investment capacity beyond the diagnosis for this industrial segment. The data may be used to support the federal government in implementing industrial policies aimed at strengthening this strategic sector for public health.
Supporting government action
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze